2 weeks Ago By Defense World Staff
Alliancebernstein L.P. lessened its position in shares of Axsome Therapeutics, Inc.
(NASDAQ:AXSM – Free Report) by 62.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,590 shares of the company’s stock after selling 78,388 shares during the quarter.
Alliancebernstein L.P. owned about 0.
10% of Axsome Therapeutics worth $3,942,000 as of its most recent SEC filing. A number of other large investors have also added to or reduced their stakes in AXSM. Intrust Bank NA grew its holdings in shares of Axsome Therapeutics by 6.
9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after purchasing an additional 183 shares in the last quarter. DnB Asset Management AS grew its stake in shares of Axsome Therapeutics by 1,100.
7% in the 4th quarter. DnB Asset Management AS now owns 73,770 shares of the company’s stock worth $6,242,000 after buying an additional 67,626 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Axsome Therapeutics by 19.
4% in the 4th quarter. Pictet Asset Management Holding SA now owns 4,678 shares of the company’s stock worth $396,000 after buying an additional 761 shares during the last quarter. Norges Bank purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $34,100,000.
Finally, LPL Financial LLC raised its position in shares of Axsome Therapeutics by 47.9% during the 4th quarter. LPL Financial LLC now owns 24,209 shares of the company’s stock valued at $2,048,000 after buying an additional 7,837 shares in the last quarter.
Institutional investors own 81.49% of the company’s stock. Axsome Therapeutics Stock Up 2.
5 %Shares of NASDAQ AXSM opened at $98.06 on Monday. The stock has a 50 day moving average price of $119.
51 and a 200 day moving average price of $102.07. The firm has a market capitalization of $4.
78 billion, a price-to-earnings ratio of -16.37 and a beta of 0.88.
Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.
13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.
04 and a current ratio of 2.11. Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th.
The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.
01. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.
83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.
47%. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.
79 earnings per share for the current year. Wall Street Analysts Forecast GrowthSeveral equities research analysts have weighed in on the company. Mizuho boosted their price objective on Axsome Therapeutics from $212.
00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $153.
00 target price on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Bank of America boosted their price objective on shares of Axsome Therapeutics from $143.
00 to $167.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada raised their target price on shares of Axsome Therapeutics from $143.
00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock.
According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $169.80.
Read Our Latest Analysis on AXSMInsiders Place Their BetsIn related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.
00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09.
This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
22.40% of the stock is owned by company insiders. About Axsome Therapeutics (Free Report)Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.Featured StoriesFive stocks we like better than Axsome TherapeuticsThe Significance of a Trillion-Dollar Market Cap Goes Beyond a NumberIs McDonald’s Stock Serving a Value Meal to Investors? What is a support level?Walgreens Comeback? Private Equity Circling for a BuyoutStocks with Unusual Volume: How to Find Unusual Volume Stocks in Real TimeCoca-Cola Stock Looks Refreshing After the Relief Rally.
